Canaccord Genuity Maintains a 'Buy' on Edwards Lifesciences (EW); ACC Preview of Cohort A
Tweet
Share
E-mailGet Alerts EW Hot Sheet
Price: $89.79 -0.04%
Rating Summary:
31 Buy, 14 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
31 Buy, 14 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Canaccord Genuity maintains a 'Buy' on Edwards Lifesciences (NYSE: EW) price target of $86.00.
Analyst, Jason R. Mills, said, "Two-year follow up on Cohort A patients will be presented at the ACC meeting next week in Chicago. We expect TAVI to maintain non-inferiority to surgical aortic valve replacement (SAVR). We think trans-femoral (T-F) patients will continue to show a better mortality rate than those who received SAVR. However, unlike Cohort B two-year results, we do not expect a widening of TAVI’s benefit vs. control, given differing patient populations and control treatment in Cohorts A vs. B. We maintain our bullish stance on the stock for long-term investors, but continue to think consensus TAVI estimates for 2012 are too high. We would be constructive on any weakness near term."
For an analyst ratings summary and ratings history on Edwards Lifesciences click here. For more ratings news on Edwards Lifesciences click here.
Shares of Edwards Lifesciences closed at $71.15 yesterday.
Analyst, Jason R. Mills, said, "Two-year follow up on Cohort A patients will be presented at the ACC meeting next week in Chicago. We expect TAVI to maintain non-inferiority to surgical aortic valve replacement (SAVR). We think trans-femoral (T-F) patients will continue to show a better mortality rate than those who received SAVR. However, unlike Cohort B two-year results, we do not expect a widening of TAVI’s benefit vs. control, given differing patient populations and control treatment in Cohorts A vs. B. We maintain our bullish stance on the stock for long-term investors, but continue to think consensus TAVI estimates for 2012 are too high. We would be constructive on any weakness near term."
For an analyst ratings summary and ratings history on Edwards Lifesciences click here. For more ratings news on Edwards Lifesciences click here.
Shares of Edwards Lifesciences closed at $71.15 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
- Bernstein SocGen on Meta Platforms Inc. (META): 'Risk-reward remains attractive'
- Benchmark Reiterates Buy Rating on Rank One Computing (ROC)
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
